Pouyan Ebrahimi: Cabozantinib Monotherapy vs Its Combination with Atezolizumab
Pouyan Ebrahimi, Medical Doctor and researcher at Babol University of Medical Sciences, shared a post on LinkedIn:
“After months of extensive research, I, along with my colleagues, am proud to announce the publication of our paper comparing the efficacy and safety of Cabozantinib monotherapy and its combination with Atezolizumab in cancer patients. This comprehensive analysis synthesizes recent clinical trials to provide an integrated view of the treatment’s effects.
Our findings show that while the combination treatment did not lead to significant improvements in Objective Response Rate (ORR) or Disease Control Rate (DCR), it was notably associated with reduced chemotherapy-related adverse events, such as nausea, vomiting, and diarrhea. This result is particularly relevant for patients who cannot tolerate standard chemotherapy regimens due to these side effects.
As the landscape of cancer treatment continues to evolve, this research provides valuable insights that could inform new therapeutic strategies. I believe this paper will contribute significantly to improving patient outcomes and enhancing our collective understanding of oncology treatments.
Finally, I encourage future clinical trials to pay close attention to the details of this study, which consolidates findings from recent trials. By carefully considering these insights, ethical decisions can be made more effectively, ensuring better treatment strategies and overall patient care in the long run.
If you have experience working on systematic reviews and are interested in collaborating on future projects, feel free to send me a direct request for collaboration. I welcome passionate researchers eager to contribute to impactful studies.”
George Vlachogiannis, Managing Editor of Cancer Control at Sage, shared this post adding:
“Analysis of the Efficacy and Safety of Cabozantinib Monotherapy Versus Its Combination with Atezolizumab in Cancer Patients: A Systematic Review and Meta-Analysis
A new systematic review and meta-analysis published in Cancer Control reports that although the combination of atezolizumab (anti-PD-L1 antibody) with cabozantinib (multi-kinase inhibitor) did not improve Objective Response Rate (ORR) or Disease Control Rate (DCR) in cancer patients versus cabozantinib alone, it was associated with lower treatment-related adverse events (diarrhea −9%, nausea −21%, vomiting −30%, hypokalemia −72%). The atezolizumab and cabozantinib combination may be a useful regimen for patients who cannot tolerate cabozantinib monotherapy.”
Title: Analysis of the Efficacy and Safety of Cabozantinib Monotherapy Versus Its Combination with Atezolizumab in Cancer Patients: A Systematic Review and Meta-Analysis
Authors: Kimia Pakdaman, Hossein-Ali Nikbakht, Amin Esmaeilnia Shirvani, Saba Sahraian, Layla Shojaie, Pouyan Ebrahimi
More posts featuring George Vlachogiannis.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023